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Abstract 1 
Cardiovascular diseases (CVD) are the leading cause of mortality and morbidity worldwide. 2 
One of the key dietary recommendations for CVD prevention is reduction of saturated fat 3 
intake. Yet despite milk and dairy foods contributing on average 27 % of saturated fat intake 4 
in the UK diet, evidence from prospective cohort studies does not support a detrimental effect 5 
of milk and dairy foods on risk of CVD. This paper provides a brief overview of the role of 6 
milk and dairy products in the diets of UK adults, and will summarise the evidence in relation 7 
to the effects of milk and dairy consumption on CVD risk factors and mortality. The majority 8 
of prospective studies and meta-analyses examining the relationship between milk and dairy 9 
product consumption and risk of CVD show that milk and dairy products, excluding butter, 10 
are not associated with detrimental effects on CVD mortality or risk biomarkers, that include 11 
serum LDL cholesterol. In addition, there is increasing evidence that milk and dairy products 12 
are associated with lower blood pressure and arterial stiffness. These apparent benefits of 13 
milk and dairy foods have been attributed to their unique nutritional composition, and suggest 14 
that the elimination of milk and dairy may not be the optimum strategy for CVD risk 15 
reduction.   16 
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Introduction 17 
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality 18 
worldwide. The World Health Organisation (WHO) estimated that 17.3 million people in the 19 
world died from CVD in 2008, including 7.3 million from coronary heart disease (CHD), and 20 
6.2 million from strokes(1). There are a number of modifiable risk factors for CVD, such as 21 
high levels of serum low-density lipoprotein cholesterol (LDL-C), hypertension, diabetes, 22 
overweight/obesity, smoking, low physical activity and diet. Indeed, diets that are rich in 23 
saturated fatty acids (SFA) and trans fatty acids (TFA) are associated with an increased risk 24 
of CVD, and it is largely agreed that this is due, in the most part, to increased serum LDL-25 
C(2). Furthermore, evidence from pharmacological studies show that lowering LDL-C by an 26 
average of 1.8 mmol/L (by use of statins) reduces risk of ischaemic heart disease (IHD) and 27 
stroke by 60 % and 17 %, respectively(3). Despite this, the relationship between SFA and 28 
CVD risk remains controversial(4).  29 
The UK dietary guidelines recommend <10 % of total energy intake from SFA, but 30 
according to the most recent National Diet and Nutrition Survey (NDNS) consumption of 31 
SFA is above these recommendations, at 11.9 % of total energy intake(5). Milk and dairy 32 
products contribute around 27 % of SFA intake in the UK diet(5). However, evidence from a 33 
number of prospective cohort studies show that consumption of particularly milk and other 34 
dairy products, except butter, are not consistently associated with an increased risk of CVD. 35 
Milk is a unique and complex food that is nutritionally complete for the sustenance of young 36 
mammals. Milk consumption in most mammals ceases soon after weaning, this coincides 37 
with down-regulation of the gene for lactase, leading to a severe compromise in the ability to 38 
digest lactose, the sugar contained within milk. However, humans are unique within the 39 
animal kingdom being the only mammal that continues to consume another animals’ milk 40 
past infancy and throughout our lifespan. This is made possible in the majority of the 41 
population by possession of one of a number of single nucleotide polymorphism (SNP) in the 42 
lactase gene, which results in persistence of lactase throughout life. The majority of 43 
individuals of European origin possess a version of the gene that remains active, which 44 
results in about 90 % of Europeans being able to digest lactose(6). Selection of these mutant 45 
SNPs in the lactase gene throughout human development suggests there may be some 46 
advantage to the ability to consume milk.  47 
This paper will provide a brief overview of the consumption of milk and dairy products in 48 
the diets of UK adults, and will summarise the evidence on the effects of milk and dairy 49 
consumption on CVD mortality and biomarkers.     50 
4 
 
Trends in milk and dairy consumption 51 
In the UK current milk consumption is around 1.5 litres of milk per person per week, with the 52 
majority of this consumed as semi-skimmed milk (70 %) followed by whole milk (20 %) and 53 
skimmed milk (10 %). Over the last few decades, trends in milk and dairy product 54 
consumption have shown considerable variation (Figure 1)(7). For example, consumption of 55 
whole milk has shown a dramatic decline since the 1970s from around 2.7 litres per person 56 
per week in 1974 to 0.3 litres per person per week in 2012 (Figure 1A). In the early 1990s the 57 
decline in whole milk consumption was partially replaced by semi-skimmed milk, 58 
consumption of which has remained fairly constant at around 1 litre per person per week over 59 
the last decade, while the intake of whole milk continues to decline. Figure 1B shows the UK 60 
trends in consumption of other dairy products such as cheese, yogurt and fromage frais, 61 
cream and butter. The trend for cheese and cream consumption has remained fairly constant 62 
at around 100 g and 20 mL per person per week for cheese and cream, respectively since the 63 
1970s. In contrast, the trend for yogurt and fromage frais consumption has increased 64 
significantly from the early 1970s with 33 mL per person per week to around 200 mL per 65 
person per week in 2012. The consumption of butter in the UK shows a similar downward 66 
trend as for whole milk, due, in part, to recommendations to reduce the amount of total and 67 
saturated fat in the diet, but also because of the increasing availability of other spreads.  68 
 69 
The contribution of milk and dairy foods to nutrient intakes 70 
Milk and dairy products are complex foods containing a number of different components. 71 
Table 1 shows the contribution of the dairy food group, which includes milk, cheese, yogurt, 72 
butter, cream and fromage frais to energy and nutrient intakes in UK adults (19-64 years)(5). It 73 
is clear that milk and other dairy products are important sources of a number of nutrients in 74 
the UK diet. Indeed, the dairy food group alone contributes more than the daily Reference 75 
Nutrient Intake (RNI) for vitamin B12 and provides around 50 % of the RNI for calcium and 76 
phosphorus. Milk and dairy products are also the main source of iodine in the UK diet, 77 
contributing about 40 % of the RNI. Adequate iodine levels are important for both men and 78 
women throughout life, but particularly in women of childbearing age as iodine levels below 79 
recommendations during pregnancy have been associated with reduced cognitive outcome of 80 
in their children(8). Although dairy is an important contribution to iodine intake in the UK 81 
diet, there have been inconsistent reports of iodine concentrations in milk with a recent study 82 
showing a 30 % lower iodine concentration in organic compared with conventional milk(9). 83 
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Therefore, although milk and dairy products are not an essential dietary component, they 84 
make an important contribution to the provision of key nutrients. 85 
 86 
Saturated fat from milk and CVD 87 
Higher dietary SFA consumption is associated with increased risk of CVD, due primarily to 88 
the serum total cholesterol and LDL-C raising effects of SFA(2). The association between 89 
SFA and increased serum LDL-C has led to dietary recommendations world-wide for the 90 
restriction of SFA intake. Dietary recommendations by the Food and Agriculture 91 
Organisation/World Health Organisation (FAO/WHO, 2010)(10), UK dietary 92 
recommendations (Department of Health, 1991)(11) and, dietary guidelines for Americans(12) 93 
recommend intake of dietary SFA to less than 10 % of total energy intake. Despite these 94 
recommendations current SFA intakes in the UK are around 11.9 % of total energy(5).   95 
Milk and dairy products are the greatest contributor to dietary SFA in the UK diet, 96 
contributing around 27 % of SFA intake. As a result, guidance to reduce or eliminate dairy 97 
from the diet has been a common practice for CVD risk reduction. However, the evidence for 98 
the relationship between dairy consumption and CVD mortality does not support dairy 99 
restriction as an effective strategy for CVD reduction. It is important to recognise that we do 100 
not consume individual nutrients, but complex foods and diets that contain specific nutrients 101 
within various matrices. This can give rise to disparity between the biological effects of 102 
nutrients in different foods that may have contributed to the inconsistencies in the 103 
relationships of different SFA-rich foods and CVD mortality. Clear evidence for this comes 104 
from the Multi Ethnic Study of Atherosclerosis (MESA), in which different SFA-rich foods 105 
were shown to produce differential effects on CVD risk(13).in 5,209 subjects after a 10 year 106 
period (from 2000 to 2010). A lower hazard ratio (HR) for CVD was reported for every 5 g/d 107 
(HR 0.79; 95 % confidence interval (CI); 0.68-0.92) or 5 % of energy from dairy SFA (HR 108 
0.62; 95 % CI 0.47- 0.82), whereas the equivalent intake of SFA from meat sources was 109 
associated with greater HR for CVD (HR for +5 g/d and a +5 % of energy from meat sources 110 
of SFA: 1.26; 95 % CI 1.02-1.54 and 1.48; 95 % CI 0.98-2.23, respectively)(13). Furthermore, 111 
the substitution of 2 % of energy from meat sources of SFA with energy from dairy SFA was 112 
associated with a 25 % lower CVD risk (HR: 0.75; 95 % CI 0.63-0.91), suggesting that dairy 113 
foods containing SFA attenuated the detrimental association of SFA with CVD mortality. 114 
While this finding was attributed to the effects of other components within dairy foods, such 115 
as calcium, magnesium, bioactive peptides and proteins, it may also have been due to a 116 
difference in the relative proportions of different SFA between meat and dairy.  117 
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Further evidence for the beneficial association between dairy and CVD, comes from an 118 
investigation of the association between plasma phospholipid fatty acids and incidence of 119 
CHD(14). In this study, the enrichment of plasma phospholipid with even chain SFA: palmitic 120 
acids (C16:0) and stearic (C18:0), but not myristic (C12:0), was associated with significantly 121 
higher risk of CHD, while the odd chain SFA indicative of dairy consumption: pentadecanoic 122 
C15:0 and hexadecanoic acid C17:0 were associated with lower risk. These finding were 123 
corroborated by associations between similar circulating biomarkers of dairy fat and the 124 
incidence of stroke in US men (Health Professionals Follow-up Study n=51,529) and women 125 
(Nurses’ Health Study n=121,700)(15). Odd chain fatty acids are found in milk and dairy 126 
products and result from bovine biohydrogenation(16). Their appearance in human plasma or 127 
tissue samples is now recognised as a specific biomarker of dairy intake, as humans are 128 
unable to synthesise these fatty acids endogenously(17). These data support the prospective 129 
cohort data that suggest that milk and dairy products are not associated with detrimental 130 
effects on CVD risk.      131 
 132 
Trans fatty acids and CVD  133 
Other important fatty acids present in milk and dairy foods are trans fatty acids (TFA), which 134 
are synthesised via bacterial metabolism of unsaturated fatty acids in the rumen of cows(18). 135 
The intake of TFA from industrially hydrogenated vegetable oils (iTFA) has a negative 136 
impact on cardiovascular health(19, 20). However, the association between ruminant TFA 137 
(rTFA) and CVD remains inconclusive(21, 22), with some studies showing a cardio-protective 138 
association(19, 23). In an attempt to resolve conflicting reports, a systematic review and meta-139 
analysis was undertaken by Bendsen et al. (2011)(24) who reported that the relative risk (RR) 140 
for high vs. low quintiles of total TFA intake (2.8 to approximately 10 g/day) was 1.22 (95 % 141 
CI 1.08–1.38; P=0.002) for CHD events and 1.24 (95 % CI 1.07–1.43; P=0.003) for fatal 142 
CHD. In addition, rTFA intake (0.5–1.9 g/day) was not significantly associated with CHD 143 
risk (RR 0.92; 95 % CI 0.76–1.11; P=0.36), although there was a trend towards a positive 144 
association for iTFA (RR 1.21; 95 % CI 0.97–1.50; P=0.09). The authors concluded that 145 
while iTFA may be positively related to CHD, rTFA were not, but the limited number of 146 
studies available prevented a firm conclusion on the critical importance of the source of TFA. 147 
In contrast to previous findings, a recent prospective cohort study by Kleber et al. (2015)(25) 148 
showed that total TFA content in erythrocyte membranes of 3,259 participants of the 149 
Ludwigshafen Risk and Cardiovascular Health Study (LURIC) was inversely associated with 150 
adverse cardiac outcomes, while rTFA (trans-palmitoleic acid) was associated with reduced 151 
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risk. In addition, erythrocyte membrane iTFA was associated with no increased risk of 152 
adverse cardiac outcomes(25). However, it is important to highlight that total TFA 153 
concentration in erythrocyte membranes in this study population was relatively low compared 154 
with levels in other studies, and this may have been too low to observe an effect of TFA on 155 
CVD mortality. Furthermore, it has been suggested that the lack of an association between 156 
rTFA and CHD risk may be due to a lower intake from ruminant sources compared with 157 
iTFA(24). Despite this controversy, there is little doubt that dietary iTFA are associated with 158 
increased CVD mortality(26). In response there has been a substantial decrease in iTFA over 159 
the past 10–15 years, due to the voluntary action by the UK food industry(27). This has led to 160 
an increase in the relative proportion of rTFA in the UK diet, although the absolute intake of 161 
ruminant fat is unchanged, with the current mean population intake of total TFA (0.7 % food 162 
energy in adults)(5) below the recommended population maximum of 2 % of food energy 163 
intake(11). Although milk and milk products (including butter) contribute to 32 % of this 164 
intake(5), current rTFA intake is not considered to be a major cause for concern with respect 165 
to cardiovascular health at a population level(22, 28). However, the impact of any increase in 166 
dietary TFA would need to be monitored.  167 
Effects of milk and dairy foods on CVD risk: evidence from observational studies 168 
The potential effects of milk and dairy consumption on CVD mortality would best be 169 
determined using adequately powered randomised control intervention studies, which have 170 
CVD events and CVD-related deaths as outcomes. However, for obvious financial and 171 
logistical reasons such studies have not been performed. The most informative data on the 172 
relationship between milk and dairy consumption and CVD is provided by long-term 173 
prospective cohort studies(29).    174 
Several influential reviews have focused on the impact milk and dairy food consumption 175 
and CVD risk, some of which have conducted meta-analyses of available cohort data (Table 176 
2)(29-32). Elwood et al. (2004)(32) conducted a meta-analyses of 10 prospective cohort studies 177 
that examined the associations between milk and risk of IHD and stroke. Using a pooled 178 
estimate of the relative odds for IHD and stroke, the meta-analysis revealed no association 179 
with IHD (RR 0.87; 95 % CI 0.74-1.03) and a significant inverse association for stroke (RR 180 
0.83; 95 % CI 0.77-0.90) in the subjects with the highest milk compared with those with the 181 
lowest intakes. These findings, together with a combined estimate of risk for both IHD and 182 
stroke (10 studies RR 0.84 95 % CI 0.78-0.90), suggested that consumption of milk was 183 
associated with a modest reduction in CVD risk. This work was extended by Elwood et al.(29) 184 
8 
 
to include 9 prospective cohort studies of milk and dairy products and IHD and 11 studies for 185 
stroke. The meta-analysis indicated a 15 % lower RR for all-cause mortality (RR: 0.85; 95 % 186 
CI 0.77-0.98) and an 8 % lower overall RR of IHD (RR: 0.92; 95 % 0.80-0.99) in the subjects 187 
with the highest dairy consumption compared with those with the lowest intakes. 188 
Furthermore, a significant inverse association was observed for the risk of stroke (RR: 0.79; 189 
95 % CI 0.68-0.91) in the subjects with the highest dairy consumption compared with those 190 
with the lowest intakes. These findings supported previous meta-analyses by Elwood and 191 
colleagues(32), and support a reduction in IHD and stroke in subjects consuming the highest 192 
amount of milk and dairy products compared with the lowest intakes.   193 
In another meta-analysis of 17 prospective cohort studies Soedamah-Muthu et al.(30) 194 
showed a modest inverse association between milk intake and risk of overall CVD (4 studies; 195 
RR: 0.94 per 200 mL/d; 95 % CI 0.89-0.99). However, milk intake was not associated with 196 
risk of CHD (6 studies; RR: 1.00 per 200 mL/d; 95 % CI 0.96-1.04), stroke (6 studies; RR: 197 
0.87; 95 % CI 0.72-1.05) or total mortality (8 studies; RR per 200 mL/d: 0.99; 95 % CI 0.95-198 
1.03). A recent meta-analysis by Qin et al. (2015)(31), which included a total of 22 prospective 199 
cohort studies, showed an inverse association between dairy consumption and overall risk of 200 
CVD (9 studies RR 0.88; 95 % CI 0.81-0.96) and stroke (12 studies RR 0.87; 95 % CI 0.77-201 
0.99). However, no association was found between dairy consumption and CHD risk (12 202 
studies RR 0.94; 95 % CI 0.82-1.07), which supports previous findings(30). Qin et al.(31) also 203 
investigated the association between individual dairy foods on risk of CVD, including stroke 204 
and CHD. Interestingly, cheese consumption was associated with a significantly reduced risk 205 
of stroke (4 studies; RR: 0.91, 95% CI 0.84-0.98) and CHD (7 studies; RR: 0.84 95% CI 206 
0.71-1.0). Recently Praagman et al. (2015)(33) also reported a significant association between 207 
cheese consumption and stroke mortality, although no impact on CHD mortality was 208 
found(33). One possible explanation for the observed beneficial effects of cheese consumption 209 
on stroke and CHD risk may be the relatively high calcium content that increases 210 
saponification of SFA in the gut, rendering them resistant to digestion leading to increased 211 
faecal fat excretion(34). This mechanism is supported by the results from a prospective cohort 212 
study in which the observed inverse association between cheese consumption and CHD was 213 
attenuated when calcium content was used as a confounder in the analysis(35). Furthermore a 214 
meta-analysis of RCT investigating the impact of calcium from dairy and dietary supplements 215 
estimated that increasing dairy calcium intake by 1241 mg/d resulted in an increase in faecal 216 
fat of 5.2 (1.6-8.8) g/d(36).  217 
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Since publication of the meta-analyses above (Table 2), additional prospective cohort 218 
studies have been published. For example, the Rotterdam Study consisting of 4,235 men and 219 
women aged 55 years and above showed that total dairy, milk, low-fat dairy, and fermented 220 
dairy were not significantly related to incident stroke or fatal stroke after a 17.3 year follow 221 
up period(37). In addition, the authors reported a significant inverse relationship between high-222 
fat dairy consumption and fatal stroke (HR 0.88 per 100 g/day; 95 % CI 0.79-0.99), but not 223 
incident stroke (HR 0.96 per 100 g/day; 95 % CI 0.90-1.02). Total dairy or individual dairy 224 
foods were not associated with incident CHD or fatal CHD.  225 
Contrary to these data, and since these meta-analyses a study conducted by Michaelsson et 226 
al. (2014)(38), reported that the milk intake was significantly associated with markedly higher 227 
total and CVD mortality and fracture risk in 61,433 Swedish women from the mammography 228 
cohort. This relationship was also observed in a cohort of 45,339 Swedish men, although the 229 
relationship was considerably weaker(38). However, the authors concluded that the study 230 
should be ‘interpreted with caution, due to the inherent possibility of residual confounding 231 
and reverse causation phenomena, which is often associated with observational study 232 
designs’. In addition, when this data was re-analysed, an inverse association was observed for 233 
the number of CVD deaths against milk consumption(39). These inconsistent findings between 234 
milk intake and CVD mortality observed with the same data set requires further investigation. 235 
Furthermore, since the study by Michaelsson et al. (2014)(38), two further large prospective 236 
cohort studies have been published on the relationship between milk and myocardial 237 
infarction and IHD mortality in Japanese (n=94,980; 19 years follow-up)(40) and Danish 238 
(n=98,529; 5.4 years follow-up)(41) populations, both of which reported no association with 239 
myocardial infarction or IHD.  240 
The balance of current evidence, including meta-analyses of prospective cohort studies, 241 
indicates that milk and dairy products are associated with no detrimental effect on risk of 242 
CVD, with some evidence of a moderately protective effect of milk consumption. However, a 243 
further meta-analysis that includes all of the current prospective cohort data is required to 244 
confirm this and more studies are required to determine the effects of individual dairy 245 
products on CVD risk.  246 
 247 
Effects of dairy on blood lipids and lipoproteins 248 
In the absence of randomised control dairy intervention studies with clinical endpoints, the 249 
bulk of evidence for cause and effect relationships between dairy foods and CVD has relied 250 
heavily upon validated CVD biomarkers as outcome measures in randomised control trials 251 
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(RCT). There is consistent evidence that consumption of dietary SFA increases total and 252 
LDL-C concentrations, a robust biomarker of CHD risk(2). Replacement of SFA with 253 
unsaturated fatty acids has a beneficial reduction on serum LDL-C and the clinically relevant 254 
total cholesterol: high-density lipoprotein cholesterol (total-C:HDL-C) ratio(2, 42, 43).  255 
However, not all classes of SFA have the same effects on blood lipids. High dietary intakes 256 
of lauric (C12:0), myristic (C14:0) and palmitic (C16:0) acids have been shown to elevate 257 
serum total and LDL-C, whereas stearic acid (C18:0) has minimal impact, due, in part, to its 258 
more limited absorption(44). These SFA are also associated with a concomitant increases in 259 
high density lipoprotein cholesterol (HDL-C) concentrations, a lipoprotein that is generally 260 
considered to be anti-atherogenic(45). This differential effect of dietary fats on different 261 
lipoprotein fractions highlights the importance of expressing dietary effects on the clinically 262 
relevant total-C:HDL-C ratio(46). Given that a high proportion of the C12:0, C14:0 and C16:0 263 
in the human diet is derived from milk fat, it would be predicted that the consumption of milk 264 
and dairy foods would be associated with adverse effects on serum LDL-C and total-C:HDL-265 
C. However, evidence indicates that diary food consumption, with the exception of butter(47), 266 
is associated with limited or no significant detriment to serum lipids. In support of this, a 267 
cross-sectional analysis of 2,512 Welsh men from the Caerphilly cohort study showed no 268 
significant difference in serum total cholesterol or LDL-C concentrations, and a significant 269 
negative association between the highest compared with the lowest quartile of dairy 270 
consumers(48). Negative associations between dairy consumption, confirmed by dietary 271 
assessment and biomarkers of dairy intake: plasma phospholipid levels of C15:0 and C17:0, 272 
and the proportion of the pro-atherogenic small dense LDLIII particles, was reported in 273 
another cross-sectional study in 291 healthy men(49). Stronger evidence from a meta-analysis 274 
of 20 randomised controlled trials with a total of 1,677 subjects showed that there was no 275 
significant change in LDL-C with either low and full-fat dairy consumption(50). In contrast, 276 
studies that used butter, invariably produced the predicted increases in LDL-C(47). This again 277 
suggests that the other components of dairy foods, such as proteins, bioactive peptides and 278 
calcium may be involved with the amelioration of the detrimental effects of dairy SFA.  279 
 280 
Differential impact of high and low-fat dairy foods 281 
There is no established nutritional benefit of whole-fat dairy consumption, except in children 282 
under 2 years, compared with lower fat alternatives. With respect to the latter, skimming milk 283 
fat to produce low-fat milk and dairy products is a common and an effective way of lowering 284 
SFA intake. However, there is currently no consensus on whether fat-reduced dairy foods are 285 
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associated with a reduced risk of CVD(50) and studies in this area give inconsistent data, with 286 
few RCT that directly compare whole with low fat alternatives. Minimal benefit has been 287 
reported in a prospective study of 33,636 women, which suggested no significant differences 288 
between consumption of high vs low fat dairy products on risk of myocardial infarction(51). 289 
Furthermore, findings from a 12-month RCT concluded that in overweight adults inclusion of 290 
reduced-fat dairy foods had no impact on blood lipids, blood pressure (BP) and arterial 291 
compliance(52). Furthermore, a meta-analysis conducted by Soedamah-Muthu et al. (2011)(30), 292 
showed that there was no significant difference between consumption of high-fat (RR: 1.04; 293 
95 % CI 0.89-1.21) or low-fat dairy (RR: 0.93; 95 % CI 0.74-1.17) on CHD risk. 294 
In contrast, data from the Nurses' Health Study cohort illustrated that the associated RR of 295 
CHD varied according to the fat content of dairy foods with an estimated 20% lower RR with 296 
low-fat dairy consumption (RR 0.80; 95 % CI 0.73–0.87) compared with a 12% higher RR 297 
with high-fat dairy consumption (RR 1.12; 95 % CI 1.05–1.20)(53). Furthermore, 298 
observational studies investigating the relationship between consumption of different types of 299 
dairy on cardio-metabolic risk factors have indicated that low-fat dairy consumption is an 300 
effective strategy to promote lower BP levels(54-56), circulating markers of inflammation(57), 301 
the ratio of total-C:HDL-C (2) and LDL-C concentration(58), as well as aid in weight 302 
maintenance or reduction(59). Further evidence from well-controlled dietary intervention 303 
studies is required before a definitive conclusion can be drawn on the benefits of low and 304 
high fat dairy. 305 
There have also been a number of studies suggesting that specific milk proteins have 306 
differential effects on lipids. Whey (60 g/day for 12 weeks) has been shown to produce 307 
significant reductions in serum triacylglycerol (TAG) and total and LDL- cholesterol in 308 
comparison to a casein control group(60). Furthermore, a significant decrease in the 309 
postprandial appearance of TAG after consuming a whey meal of 21 % compared to control 310 
and 27 % compared to the casein meals were reported(61). In addition to specific dairy 311 
proteins, different dairy foods have been shown to have a range of lipid effects(62). It has been 312 
reported that cheese may have a differential effect on blood lipids compared with other dairy 313 
foods(34, 63, 64), with prolonged ripening of cheddar cheese resulting in more pronounced lipid-314 
lowering effects in a pig model(65). A meta-analysis that included five of these randomised 315 
control studies showed that when compared with butter intake, cheese consumption reduced 316 
LDL-C by 6.5 % (-0.22 mmol/L; 95 % -0.2 to -0.14) and HDL-C by 3.9 % (-0.05 mmol/L 95 317 
% CI -0.09 to -0.02) but had no effect on TAG(66). In addition, a recent RCT reported that 318 
consumption of 80 g/day of a high fat cheese (27 % fat) compared with no cheese or 50 g/day 319 
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of fat and salt-free cheese for 8 weeks resulted in no changes in total or LDL-C. Those in the 320 
high fat cheese group with metabolic syndrome at baseline had significant reductions in total 321 
cholesterol (-0.70 mmol/l) compared with control and a significantly higher reduction in 322 
TAG(67). These data show that dairy products do not exert the negative effects on blood lipids 323 
which would be predicted solely from their SFA content, and highlights a need for additional 324 
studies before firmer conclusions can be made on the differential effects of dairy products on 325 
serum lipid and lipoprotein concentrations.   326 
Overall, the current evidence presented in this section suggests that the fatty acid profile of 327 
milk may not be as detrimental for lipid risk factors as previously thought, and supports 328 
differential effects of dairy foods, particularly cheese.   329 
 330 
Manipulating the fatty acid profile of milk  331 
Modification of the fatty acid profile of bovine milk offers an alternate strategy for lowering 332 
the population's intake of SFA, by removing SFA from the food chain, while preserving the 333 
beneficial contributions that dairy products make to the protein and micronutrient content of 334 
the human diet(68). Partial replacement of milk SFA with cis-monounsaturated fatty acids (cis-335 
MUFA) or cis-polyunsaturated fatty acids (cis-PUFA) through supplementation of the cows’ 336 
diet with plant oils or oilseeds reduces synthesis of short- and medium-chain SFA by the 337 
bovine mammary gland, and increases the long-chain (>C18) unsaturated fatty acid 338 
concentration in the milk(69, 70). Inclusion of 49 g/kg of dry matter of rapeseed oil in the 339 
ruminant diet for a 28-day period increased cis-MUFA from 20 to 33 g/100 g fatty acids, 340 
while reducing SFA from 70 to 55 to 60 g/day fatty acids(71). This feeding regimen 341 
inadvertently leads to increased concentrations of naturally produced rTFA, predominantly 342 
trans-linoleic acid (trans-18:1) and trans-MUFA, in the milk. However, despite this increase 343 
in rTFA, the consumption of the modified dairy products is not thought to have a major 344 
impact on CVD risk(25). In addition, cell culture studies have shown that rTFA has minimal 345 
impact on endothelial function and gene expression(72), though whether rTFA intake, through 346 
manipulation of the fatty acid profile of milk and dairy products to decrease SFA content, 347 
impacts on cardiovascular health, has yet to be determined.  348 
Consumption of SFA-reduced milk and milk products, by feed modification has been 349 
shown to be beneficial to CVD risk, in healthy and hypercholesterolaemic populations when 350 
compared to conventional dairy products(73). Poppitt et al. (2002) demonstrated that 351 
consumption of 20 % energy per day as conventional or feed-modified SFA-reduced butter 352 
for a 3 week period resulted in significant reduction in both total cholesterol and LDL-C 353 
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during the modified butter feeding(74). However, the evidence is relatively limited and the 354 
majority of studies have used butter only and relied on serum lipid levels as biomarkers of 355 
CVD risk. This knowledge gap is being addressed at the University of Reading with the 356 
RESET (REplacement of SaturatEd fat in dairy on Total cholesterol) Study investigating the 357 
impact of reducing SFA intake by using modified milk and dairy products on vascular 358 
function and CVD risk biomarkers, without limiting dairy product consumption. Milk that 359 
has a substantial proportion of SFA replaced with cis- MUFA will be collected from cows fed 360 
a diet supplemented with 1 kg/day of high-oleic sunflower oil. Cheddar cheese and butter will 361 
be produced from this milk and these dairy foods will be supplied to volunteers with 362 
increased CVD risk for a 12-week period in a randomised, crossover, double-blind, 363 
controlled study. The impact of these modified dairy products on fasted and postprandial 364 
vascular function, blood pressure, lipids, insulin sensitivity and inflammatory biomarkers will 365 
be determined relative to typical commercially available products. The project, which started 366 
in late 2013, will provide unique evidence of the physiological effects of modified SFA-367 
reduced dairy products, which could contribute to food-based dietary recommendations for 368 
CVD risk reduction. 369 
 370 
Effects of milk and dairy products on blood pressure and arterial stiffness 371 
Hypertension, defined as systolic BP ≥140 mm Hg and/or diastolic BP of ≥90 mm Hg, is one 372 
of the leading risk factors in the development of stroke, CHD, heart failure and end stage 373 
renal disease(75). BP is a modifiable by environmental and lifestyle factors, with diet as one of 374 
the most important mediators(76). The Dietary Approaches to Stop Hypertension (DASH) trial 375 
demonstrated that a diet consisting of reduced total and SFA fats, high intakes of low-fat 376 
dairy products, and fruit and vegetables significantly lowered BP in normotensive and 377 
hypertensive individuals(77). Moreover, the magnitude of BP reduction was of greater 378 
magnitude after the diet rich in low-fat dairy products compared with the fruit and vegetable 379 
rich diet, which omitted dairy products altogether(77). The findings from cross-sectional and 380 
prospective studies have shown an inverse association between consumption of dairy 381 
products, particularly low-fat varieties and risk of hypertension(48, 56, 78-84). These findings 382 
were confirmed in a meta-analysis by Soedamah-Muthu et al. (2012)(84), in which nine 383 
prospective cohort studies and a total of 57,256 participants, showed a reduced RR for 384 
hypertension (pooled RR: 0.97; 95 % CI, 0.95-0.99 per 200 g/day) and intake of total 385 
dairy(84). A few RCTs have examined the effects of dairy products on BP(56, 85, 86). For 386 
example, a randomised cross-over trial by Van Meijl and Mensink (2011)(56) in 35 healthy 387 
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overweight and obese men and women indicated that daily consumption of low-fat dairy 388 
products compared with carbohydrate-rich products for 8 weeks, significantly reduced 389 
systolic BP by 2.9 mm Hg. However, a recent study by Maki and colleagues (2013)(86) 390 
observed no significant effects of consuming low-fat dairy products, compared with low-fat 391 
non-dairy products, on BP in 62 men and women with prehypertension or stage 1 392 
hypertension(86).  393 
The impact of dairy foods on BP and other more novel markers of vascular health are 394 
becoming increasingly relevant. Increased central arterial stiffening is a hallmark of the 395 
ageing process and the consequence of many diseases such as diabetes, atherosclerosis and 396 
chronic renal failure. Arterial stiffness is also a marker for increased CVD risk, including 397 
myocardial infarction(87), heart failure(88) and total mortality(89), as well as stroke(90) and renal 398 
disease(91). Arterial stiffness is measured by pulse wave velocity and augmentation index, 399 
both of which are predictive of heart attacks and stroke (92) and all-cause mortality(93). Pulse 400 
wave velocity measures the speed of propagation along the artery, whereas augmentation 401 
index is calculated from the blood pressure wave form and is based on the degree of wave 402 
reflection. Significant relationships between dairy product intake and arterial pulse wave 403 
velocity have been shown in a cross-sectional(94) and longitudinal(48) cohort studies. 404 
Livingstone et al. (2013)(48) used data from the Caerphilly Prospective Study, based on 2,512 405 
men followed for a mean of 15 years and showed a significant inverse relationship between 406 
dairy product intake and augmentation index. The subjects in the highest quartile of dairy 407 
product intake (mean 480 g/day), excluding butter, had 2 % (P=0.02) lower augmentation 408 
index compared with subjects with the lowest dairy intake (mean 154 g/day), whereas across 409 
increasing quartiles of butter intake there was no impact on augmentation index, but a 410 
significant increase in insulin, serum triacylglycerol and total cholesterol concentrations, and 411 
diastolic BP(48).  412 
The mechanisms by which milk and dairy products may reduce BP and arterial stiffness 413 
are unclear. It has been hypothesised that bioactive peptides released during milk protein 414 
digestion, dairy fermentation or industrially by enzyme or chemical treatments, may be 415 
involved in the relationship between dairy consumption and BP(95, 96). It has been proposed 416 
that these bioactive peptides may inhibit the action of angiotensin I converting enzyme, 417 
thereby reducing blood levels of angiotensin, preventing blood vessel constriction, and 418 
modulating endothelial integrity. Ballard et al. (2009)(97) showed that consumption of 5 g of 419 
whey-derived peptide daily for a 2 week period significantly improved brachial artery flow-420 
mediated dilation response(97). A further study reported that although whey and casein exerted 421 
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similar hypotensive effects, whey protein supplementation (60 g/day for 12 weeks) 422 
significantly reduced augmentation index compared with casein (60 g/day for 12 weeks)(98), 423 
an effect that requires confirmation. There is also evidence to suggest that certain peptides 424 
from milk proteins may modulate the release of vasoconstrictor endothelin-1 by endothelial 425 
cells, thus preventing an increase in blood pressure(99). Milk also contains a variety of other 426 
biologically active components such as calcium, potassium and magnesium that may exert 427 
impact on blood pressure and arterial stiffness(100).                                                                                                                                                     428 
 429 
Conclusions  430 
The weight of existing evidence indicates that milk and dairy products (excluding butter) are 431 
not associated with detrimental effects on CVD risk factors and mortality, and may even 432 
exert favourable effects on CVD risk, by lowering blood pressure and arterial stiffness. While 433 
the specific mechanisms that underpin these effects are not clear, the unique nutritional 434 
composition of milk and dairy foods has been implicated in improving vascular function and 435 
in attenuating the LDL cholesterol-raising property of SFA. Our current dietary guideline to  436 
reduce intake of dietary SFA to 10 % of total energy to lower CVD risk is still valid, but the 437 
elimination of milk and dairy from our diet is clearly not an evidence-based strategy for 438 
achieving this aim.   439 
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Tables 
 
Table 1 Energy and major nutrients provided by milk and dairy products to adults (19-64 years) diets in the UK 
  1% Fat 
Milk 
Butter Cheese Ice cream Other milk 
and cream 
Semi-
skimmed 
milk 
Skimmed 
milk 
Whole 
milk 
Yoghurt, 
fromage frais 
and dairy 
desserts 
Total dairy 
contribution 
Energy Intake (MJ/d) 0.0 0.1 0.2 0.0 0.1 0.2 0.0 0.1 0.1 0.8 
 % of EAR1 0.0 1.0 2.2 0.4 0.6 1.7 0.3 0.6 0.9 7.8 
Total fat Intake (g/d) 0.0 2.8 4.8 0.6 1.2 1.6 0.0 1.0 0.7 12.7 
 % of DRV2 0.0 3.2 6.4 0.9 0.9 2.5 0.0 1.4 1.0 16.3 
Saturated fat Intake (g/d) 0.0 1.7 3.0 0.4 0.7 1.0 0.0 0.6 0.4 7.9 
 % of DRV 0.0 4.8 10.6 1.5 1.6 4.4 0.0 2.2 1.6 26.6 
Protein Intake (g/d) 0.1 0.0 3.7 0.2 0.4 3.4 0.7 0.8 1.2 10.5 
 % of RNI3 0.1 0.0 6.8 0.3 0.7 6.3 1.2 1.5 2.2 19.1 
Potassium  Intake (mg/d) 2.6 0.9 14.5 9.1 18.3 154.0 31.9 37.7 59.2 328.2 
 % of RNI 0.1 0.0 0.4 0.3 0.5 4.4 0.9 1.1 1.7 9.4 
Calcium Intake (mg/d) 2.0 0.6 102.4 5.2 11.7 118.3 24.2 28.8 39.3 332.4 
 % of RNI 0.3 0.1 14.6 0.7 1.7 16.9 3.5 4.1 5.6 47.5 
Phosphorus Intake (mg/d) 1.6 0.8 74.7 4.8 11.2 94.6 19.1 23.1 36.0 265.8 
 % of RNI 0.3 0.1 13.6 0.9 2.0 17.2 3.5 4.2 6.5 48.3 
Magnesium Intake (mg/d) 0.2 0.1 4.2 0.8 1.7 10.0 2.3 2.5 4.2 25.9 
 % of RNI 0.1 0.0 1.4 0.3 0.6 3.3 0.8 0.8 1.4 8.6 
Zinc Intake (mg/d) 0.0 0.0 0.5 0.0 0.1 0.4 0.1 0.1 0.1 1.4 
 % of RNI 0.1 0.0 5.7 0.2 0.5 4.2 1.0 1.0 1.5 14.3 
Iodine Intake (µg/d) 0.6 1.3 4.6 1.5 2.9 25.5 5.7 6.9 8.5 57.6 
 % of RNI 0.4 0.9 3.3 1.1 2.1 18.2 4.1 4.9 6.1 41.1 
Riboflavin Intake (mg/d) 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.1 0.1 0.5 
 % of RNI 0.3 0.1 4.6 1.1 1.6 17.5 3.3 4.3 4.4 37.3 
Vitamin B12 Intake (µg/d) 0.0 0.0 0.3 0.0 0.0 0.8 0.2 0.2 0.1 1.6 
 % of RNI 1.0 0.5 22.0 1.9 2.8 50.9 10.6 12.2 5.4 107.3 
Vitamin B5 Intake (mg/d) 0.0 0.0 0.1 0.0 0.0 0.7 0.1 0.1 0.1 1.2 
 % of RNI 0.3 0.1 1.5 0.9 0.7 13.7 1.8 2.7 2.7 24.3 
1 EAR, estimated average requirement. 
2 DRV, daily recommended value. 
3 RNI, reference nutrient intake. 
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Figure 1. Trends in milk, cheese, yogurt and fromage frais, cream and butter purchase, 1974-
2012. Source: AHDB Dairy. 
 
 
A
ve
ra
g
e
 p
u
rc
h
as
e
/p
e
rs
o
n
/w
e
e
k
 (
li
tr
e
s)
1970 1980 1990 2000 2010
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Whole milk Semi-skimmed milk
Skimmed milk Total milk
A
ve
ra
g
e
 p
u
rc
h
as
e
/p
e
rs
o
n
/w
e
e
k
 (
g
ra
m
)
1970 1980 1990 2000 2010
0
50
100
150
200
250
Cheese Yogurt & fromage frais
Cream Butter
A
B
26 
 
Table 2. Summary of recent reviews and meta-analyses on milk or total dairy intake and risk of CVD 
Reference Dairy food Methodology Overall CVD Stroke CHD IHD 
Elwood et al (2004)(32) Milk 
Meta-analysis. 10 
prospective cohorts 
Inverse association 
(RR=0.84; 95% CI 
0.78-0.90) 
Inverse association 
(RR=0.83; 95% CI 
0.77-0.90) 
 
No association 
(RR=0.87; 95% CI 
0.74-1.03) 
Elwood et al (2010)(29) 
Total dairy and/or 
milk 
 
Meta-analysis. 19 
prospective cohorts 
 
Inverse association 
(RR=0.79; 95% CI 
0.68-0.91) 
 
Inverse association 
(RR=0.92; 95% CI 
0.80-0.99) 
Soedamah-Muthu et al 
(2011)(30) 
Milk 
Meta-analysis. 17 
prospective cohorts 
Inverse association 
(RR=0.94, 95% CI 
0.89-0.99) 
No association 
(RR=0.87, 95% CI 
0.72-1.05) 
No association 
(RR=1.0, 95% CI 
0.96-1.04) 
 
Qin et al (2015)(31) 
Total dairy 
 
 
 
High-fat dairy 
 
 
 
Low-fat dairy 
 
 
 
Yogurt 
 
 
 
Cheese 
 
 
 
Butter 
Meta-analysis: 22 
prospective cohorts 
 
 
 
Inverse association 
(RR=0.88, 95% CI 
0.81-0.96) 
 
 
Inverse association 
(RR=0.87, 95% CI 
0.77-0.99) 
 
No association 
(RR=0.95, 95% CI 
0.83-1.08) 
 
Inverse association 
(RR=0.93, 95% CI 
0.88-0.99) 
 
No association 
(RR=0.98, 95% CI 
0.92-1.06) 
 
Inverse association 
(RR=0.91, 95% CI 
0.84-0.98) 
 
No association 
(RR=0.94, 95% CI 
0.84-1.06) 
No association 
(RR=0.94, 95% CI 
0.82-1.07) 
 
No association 
(RR=1.08, 95% CI 
0.99-1.17) 
 
No association 
(RR=1.02, 95% CI 
0.92-1.14) 
 
No association 
(RR=1.06, 95% CI 
0.90-1.34) 
 
Inverse association 
(RR=0.84, 95% CI 
0.71-1.00) 
 
No association 
(RR=1.02, 95% CI 
0.88-1.20) 
 
CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; IHD, ischaemic heart disease, RR; relative risk 
